A Phase 3 interventional study of brentuximab vedotin and placebo in Disease, Hodgkin, sponsored by Seagen Inc.. Completed at 87 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-14.
Sponsored by Seagen Inc. (part of Pfizer) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies testing Brentuximab Vedotin in Hodgkin Disease — 14 open to participants now, 28 under way, 8 of them phase 3. Brentuximab Vedotin · Hodgkin Disease.
Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, this one is the 8th largest by enrollment, is one of 3 that started in 2010, is one of 8 in phase 3, and was the 8th registered.
1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.
Browse Hodgkin Disease studies →14 of the 80 studies testing Brentuximab Vedotin in Hodgkin Disease are open now, in 12 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
University of Miami · Sites in United States
Ages 18–60
Children's Cancer Group, China · Sites in China
Ages 2–35
Takeda · Sites in India
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 56 · Phase 3 11 · Phase 4 2
First in 2006; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 329 is above the median of 40 across 1,095 interventional studies indexed under Hodgkin Disease.
Median enrollment 52 across the 80 interventional studies. Of the 46 that completed or were terminated, 26 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 80 have an industry lead sponsor. The 10 most frequent:
This study is registered under Seagen Inc., one of the names counted as Pfizer. Under that name alone:
Seagen Inc. is the lead sponsor of 88 studies on the registry; 1 is open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 14 (52%) have results posted.
22 studies in Hodgkin Disease by Pfizer: none open now, none under way, none of them phase 3. Of 21 finished, 10 (48%) have results posted.
Among the 22 studies in Hodgkin Disease by Pfizer, this one has the largest enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2010, is one of 2 in phase 3, and was the 10th registered.
Pfizer’s Hodgkin Disease studies by the year they started, since 2000.
7 of the studies testing Brentuximab Vedotin in Hodgkin Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05180097Canadian Cancer Trials GroupPembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma | 2026-12-31 |
| NCT03755804St. Jude Children's Research HospitalPediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 | 2027-01-01 |
| NCT06377566Memorial Sloan Kettering Cancer CenterA Study of BV-AVD in People With Bulky Hodgkin Lymphoma | 2027-04 |
| NCT04561206City of Hope Medical CenterBrentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | 2027-10-02 |
| NCT05404945University of VirginiaFitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above | 2027-10-03 |
Add all 7 to your calendar (.ics) → With an account.
Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, from their registry updates:
Among Pfizer’s 22 in Hodgkin Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, placebo-controlled, multicenter phase 3 trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) and best supportive care (BSC) compared to placebo and BSC in treatment of residual Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion
Drug: brentuximab vedotin
placebo every 3 weeks by IV infusion
Drug: placebo
Every 21 days by IV infusion (1.8 mg/kg)
Also known as: SGN-35, Adcetris
Every 21 days by IV infusion
Progression-free Survival by Independent Review
Time from date of randomization to the first documentation of disease progression by independent review or to death due to any cause, whichever comes first
Time frame: Up to approximately 4 years
Overall Survival
Time from date of randomization to date of death due to any cause
Time frame: Up to approximately 10 years
Incidence of Adverse Events or Laboratory Abnormalities
Time frame: Up to 12 months
Incidence of Anti-therapeutic Antibodies (ATA) to Brentuximab Vedotin
Time frame: Up to 12 months
Apr 2010-Aug 2014
| Milestone | Brentuximab Vedotin | Placebo |
|---|---|---|
| Started | 165 | 164 |
| Completed | 89 | 70 |
| Not completed | 76 | 94 |
| Withdrew: Withdrawal by subject | 18 | 25 |
| Withdrew: Lost to follow-up | 13 | 28 |
| Withdrew: Site request to end participation in study | 0 | 1 |
| Withdrew: Death | 45 | 40 |
Time from date of randomization to the first documentation of disease progression by independent review or to death due to any cause, whichever comes first
| months | Brentuximab Vedotin | Placebo |
|---|---|---|
| Progression-free Survival by Independent Review | 42.9 (30.4 to 42.9) | 24.1 (11.5 to NA) |
Time from date of randomization to date of death due to any cause
| months | Brentuximab Vedotin | Placebo |
|---|---|---|
| Overall Survival | NA (1.31 to 117.88) | NA (0.03 to 119.23) |
| participants | Brentuximab Vedotin | Placebo |
|---|---|---|
| Any Treatment-Emergent Adverse Event | 163 | 142 |
| Any Treatment-Related Adverse Event | 147 | 79 |
| Any Adverse Event with Severity >= Grade 3 | 93 | 51 |
| Any Serious Adverse Event | 41 | 20 |
| Any Treatment-Related Serious Adverse Events | 19 | 7 |
| Treatment Discontinuation Due to Adverse Event | 54 | 10 |
| Any Laboratory Abnormalities Severity >=Grade 3 | 69 | 29 |
| participants | Brentuximab Vedotin | Placebo |
|---|---|---|
| Baseline Negative | 138 | 142 |
| Baseline Negative: -'ve Postbaseline | 92 | 104 |
| Baseline Negative: Transiently +'ve Postbaseline | 36 | 27 |
| Baseline Negative: Persistently +'ve Postbaseline | 10 | 11 |
| Baseline Positive | 19 | 12 |
| Baseline Positive: -'ve Postbaseline | 7 | 0 |
| Baseline Positive: Transiently +'ve Postbaseline | 9 | 5 |
| Baseline Positive: Persistently +'ve Postbaseline | 3 | 7 |
Collected over Non-serious adverse events were followed for up to 15 months. Serious adverse event data were collected for up to approximately 10 years (116 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 40/160 (25%) | 21/160 (13.1%) | 127/160 (79.4%) |
| Brentuximab Vedotin | 45/167 (26.9%) | 43/167 (25.7%) | 151/167 (90.4%) |
| Event | Placebo | Brentuximab Vedotin |
|---|---|---|
| PneumoniaInfections and infestations | 4/160 | 7/167 |
| PyrexiaGeneral disorders | 2/160 | 6/167 |
| VomitingGastrointestinal disorders | 1/160 | 5/167 |
| NauseaGastrointestinal disorders | 1/160 | 4/167 |
| HepatotoxicityHepatobiliary disorders | 1/160 | 3/167 |
| Peripheral sensory neuropathyNervous system disorders | 0/160 | 3/167 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/160 | 0/167 |
| ConstipationGastrointestinal disorders | 0/160 | 2/167 |
| Herpes zosterInfections and infestations | 1/160 | 2/167 |
| HeadacheNervous system disorders | 0/160 | 2/167 |
| Event | Placebo | Brentuximab Vedotin |
|---|---|---|
| Peripheral sensory neuropathyNervous system disorders | 25/160 | 92/167 |
| NeutropeniaBlood and lymphatic system disorders | 18/160 | 58/167 |
| Upper respiratory tract infectionInfections and infestations | 37/160 | 43/167 |
| FatigueGeneral disorders | 29/160 | 40/167 |
| Peripheral motor neuropathyNervous system disorders | 3/160 | 37/167 |
| CoughRespiratory, thoracic and mediastinal disorders | 26/160 | 35/167 |
| NauseaGastrointestinal disorders | 12/160 | 34/167 |
| DiarrhoeaGastrointestinal disorders | 15/160 | 33/167 |
| Weight decreasedInvestigations | 9/160 | 31/167 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 15/160 | 30/167 |
Intention-to-Treat analysis set
| Age, Continuous(years) | Brentuximab Vedotin | Placebo | Total |
|---|---|---|---|
| Median | 33 (18 to 71) | 32 (18 to 76) | 32 (18 to 76) |
| Sex: Female, Male(Participants) | Brentuximab Vedotin | Placebo | Total |
|---|---|---|---|
| Female | 89 | 67 | 156 |
| Male | 76 | 97 | 173 |
| Race (NIH/OMB)(Participants) | Brentuximab Vedotin | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 3 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 10 | 2 | 12 |
| White | 153 | 156 | 309 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 3 | 3 |
| Region of Enrollment(Participants) | Brentuximab Vedotin | Placebo | Total |
|---|---|---|---|
| Russian Federation | 20 | 19 | 39 |
| Romania | 4 | 6 | 10 |
| Hungary | 9 | 11 | 20 |
| United States | 67 | 68 | 135 |
| United Kingdom | 3 | 3 | 6 |
| Spain | 4 | 6 | 10 |
| Czech Republic | 5 | 0 | 5 |
| Poland | 26 | 28 | 54 |
| Italy | 9 | 7 | 16 |
| France | 8 | 5 | 13 |
| Serbia | 3 | 6 | 9 |
| Bulgaria | 7 | 2 | 9 |
| Germany | 0 | 3 | 3 |
| Eastern Cooperative Oncology Group Performance Status(Participants) | Brentuximab Vedotin | Placebo | Total |
|---|---|---|---|
| 0 | 87 | 97 | 184 |
| 1 | 77 | 67 | 144 |
| 2 | 1 | 0 | 1 |
| Hodgkin Lymphoma Status after end of Frontline Therapy(Participants) | Brentuximab Vedotin | Placebo | Total |
|---|---|---|---|
| Refractory | 99 | 97 | 196 |
| Relapse in less than 12 months | 53 | 54 | 107 |
| Relapse 12 months or later with extranodal disease | 13 | 13 | 26 |
| Best Response to Salvage Therapy pre-ASCT(Participants) | Brentuximab Vedotin | Placebo | Total |
|---|---|---|---|
| Complete remission | 61 | 62 | 123 |
| Partial remission | 57 | 56 | 113 |
| Stable disease | 47 | 46 | 93 |
Ran from Apr 2010 to primary completion in Aug 2014, 52 months.
Results were first posted in Nov 2015, 1 year 2 months after primary completion.
Of 33 phase 3 interventional studies under Hodgkin Disease, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 108. This study's 52 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brentuximab Vedotin